Bristol-Myers Squibb is a leading pharmaceutical company with a strong pipeline. However, the stock is been stagnant in 2020 and therefore remains significantly undervalued here at the beginning of 2021. With this video I attempt to illustrate reasons why the market has been neglecting this blue-chip and then elaborate on whether it is justified or not.
Disclosure: Long BMY.
Disclaimer: The opinions in this document are for informational and educational purposes only and should not be construed as a recommendation to buy or sell the stocks mentioned or to solicit transactions or clients. Past performance of the companies discussed may not continue and the companies may not achieve the earnings growth as predicted. The information in this document is believed to be accurate, but under no circumstances should a person act upon the information contained within. We do not recommend that anyone act upon any investment information without first consulting an investment advisor as to the suitability of such investments for his specific situation.